Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates

Pochetti G, Gavuzzo E, Campestre C, Agamennone M, Tortorella P, Consalvi V, Gallina C, Hiller O, Tschesche H, Tucker PA, Mazza F (2006)
JOURNAL OF MEDICINAL CHEMISTRY 49(3): 923-931.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ;
Abstract / Bemerkung
Potent and selective inhibitors of matrix metalloproteinases (MMPs), a family of zinc proteases that can degrade all the components of the extracellular matrix, could be useful for treatment of diseases such as cancer and arthritis. The most potent MMP inhibitors are based on hydroxamate as zinc-binding group (ZBG). alpha-Arylsulfonylamino phosphonates incorporate a particularly favorable combination of phosphonate as ZBG and arylsulfonylamino backbone so that their affinity exceptionally attains the nanomolar strength frequently observed for hydroxamate analogues. The detailed mode of binding of [1-(4'-methoxybiphenyl-4-sulfonylamino)-2-methylpropyl]phosphonate has been clarified by the crystal structures of the complexes that the R- and S-enantiomers respectively form with MMP-8. The reasons for the preferential MMP-8 inhibition by the R-phosphonate are underlined and the differences in the mode of binding of analogous alpha-arylsulfonylamino hydroxamates and carboxylates are discussed.
Erscheinungsjahr
Zeitschriftentitel
JOURNAL OF MEDICINAL CHEMISTRY
Band
49
Zeitschriftennummer
3
Seite
923-931
ISSN
PUB-ID

Zitieren

Pochetti G, Gavuzzo E, Campestre C, et al. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY. 2006;49(3):923-931.
Pochetti, G., Gavuzzo, E., Campestre, C., Agamennone, M., Tortorella, P., Consalvi, V., Gallina, C., et al. (2006). Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY, 49(3), 923-931. doi:10.1021/jm050787+
Pochetti, G., Gavuzzo, E., Campestre, C., Agamennone, M., Tortorella, P., Consalvi, V., Gallina, C., Hiller, O., Tschesche, H., Tucker, P. A., et al. (2006). Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY 49, 923-931.
Pochetti, G., et al., 2006. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY, 49(3), p 923-931.
G. Pochetti, et al., “Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates”, JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, 2006, pp. 923-931.
Pochetti, G., Gavuzzo, E., Campestre, C., Agamennone, M., Tortorella, P., Consalvi, V., Gallina, C., Hiller, O., Tschesche, H., Tucker, P.A., Mazza, F.: Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY. 49, 923-931 (2006).
Pochetti, G, Gavuzzo, E, Campestre, C, Agamennone, M, Tortorella, P, Consalvi, V, Gallina, C, Hiller, O, Tschesche, Harald, Tucker, PA, and Mazza, F. “Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates”. JOURNAL OF MEDICINAL CHEMISTRY 49.3 (2006): 923-931.

24 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview.
Adhikari N, Mukherjee A, Saha A, Jha T., Eur J Med Chem 129(), 2017
PMID: 28219048
Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids.
Luisi G, Angelini G, Gasbarri C, Laghezza A, Agamennone M, Loiodice F, Supuran CT, Campestre C, Tortorella P., J Enzyme Inhib Med Chem 32(1), 2017
PMID: 28948845
In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover.
De Colli M, Tortorella P, Marconi GD, Agamennone M, Campestre C, Tauro M, Cataldi A, Zara S., Clin Oral Investig 20(8), 2016
PMID: 26689567
Regulation and involvement of matrix metalloproteinases in vascular diseases.
Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U., Front Biosci (Landmark Ed) 21(), 2016
PMID: 26709763
Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity.
Tauro M, Laghezza A, Loiodice F, Piemontese L, Caradonna A, Capelli D, Montanari R, Pochetti G, Di Pizio A, Agamennone M, Campestre C, Tortorella P., J Enzyme Inhib Med Chem 31(sup4), 2016
PMID: 27556138
Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.
Maize KM, Kurbanov EK, Johnson RL, Amin EA, Finzel BC., FEBS Lett 589(24 pt b), 2015
PMID: 26578066
Synthesis and antitumor activities of novel rhein α-aminophosphonates conjugates.
Yao GY, Ye MY, Huang RZ, Li YJ, Pan YM, Xu Q, Liao ZX, Wang HS., Bioorg Med Chem Lett 24(2), 2014
PMID: 24378217
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Tauro M, Loiodice F, Ceruso M, Supuran CT, Tortorella P., Bioorg Med Chem Lett 24(12), 2014
PMID: 24813742
Synthesis, cytotoxicity, DNA binding and apoptosis of rhein-phosphonate derivatives as antitumor agents.
Ye MY, Yao GY, Wei JC, Pan YM, Liao ZX, Wang HS., Int J Mol Sci 14(5), 2013
PMID: 23629673
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P., Bioorg Med Chem 21(21), 2013
PMID: 24071448
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption.
Rubino MT, Agamennone M, Campestre C, Campiglia P, Cremasco V, Faccio R, Laghezza A, Loiodice F, Maggi D, Panza E, Rossello A, Tortorella P., ChemMedChem 6(7), 2011
PMID: 21714093
Identification of novel matrix metalloproteinase inhibitors by screening of phenol fragments library.
Rubino MT, Maggi D, Laghezza A, Loiodice F, Tortorella P., Arch Pharm (Weinheim) 344(9), 2011
PMID: 21695711
Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.
Dormán G, Cseh S, Hajdú I, Barna L, Kónya D, Kupai K, Kovács L, Ferdinandy P., Drugs 70(8), 2010
PMID: 20481653
Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.
Rubino MT, Agamennone M, Campestre C, Fracchiolla G, Laghezza A, Loiodice F, Nuti E, Rossello A, Tortorella P., ChemMedChem 4(3), 2009
PMID: 19204958
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Augé F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J., Bioorg Med Chem 16(18), 2008
PMID: 18782669
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.
Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C., Bioorg Med Chem 15(2), 2007
PMID: 17088065
Novel hydroxamic acid-related phosphinates: inhibition of neutral aminopeptidase N (APN).
Drag M, Grzywa R, Oleksyszyn J., Bioorg Med Chem Lett 17(6), 2007
PMID: 17270439
Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.
Gerhardt S, Hassall G, Hawtin P, McCall E, Flavell L, Minshull C, Hargreaves D, Ting A, Pauptit RA, Parker AE, Abbott WM., J Mol Biol 373(4), 2007
PMID: 17897672
Recent advances in MMP inhibitor design.
Fisher JF, Mobashery S., Cancer Metastasis Rev 25(1), 2006
PMID: 16680577

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 16451058
PubMed | Europe PMC

Suchen in

Google Scholar